Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone.

Govi S, Christie D, Messina C, Bruno Ventre M, Gracia Medina EA, Porter D, Radford J, Seog Heo D, Park Y, Martinelli G, Taylor E, Lucraft H, Ballova V, Zucca E, Gospodarowicz M, Ferreri AJ; International Extranodal Lymphoma Study Group (I.E.L.S.G.).

Ann Oncol. 2014 Jan;25(1):176-81. doi: 10.1093/annonc/mdt482. Epub 2013 Nov 28.

PMID:
24287938
2.

Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).

Bruno Ventre M, Ferreri AJ, Gospodarowicz M, Govi S, Messina C, Porter D, Radford J, Heo DS, Park Y, Martinelli G, Taylor E, Lucraft H, Hong A, Scarfò L, Zucca E, Christie D; International Extranodal Lymphoma Study Group.

Oncologist. 2014 Mar;19(3):291-8. doi: 10.1634/theoncologist.2013-0249. Epub 2014 Feb 24.

3.

Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).

Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, Radford J, Heo DS, Park HY, Pro B, Jayamohan J, Visco C, Scarfò L, Zucca E, Gospodarowicz M, Christie D; International Extranodal Lymphoma Study Group (I.E.L.S.G.).

Br J Haematol. 2014 Mar;164(6):834-40. doi: 10.1111/bjh.12714. Epub 2014 Jan 2.

PMID:
24383942
4.

Prognostic factors and treatment efficacy in patients with primary diffuse large B-cell lymphoma of the bone: single institute experience over 11 years.

Liu YC, Gau JP, Yu YB, Hong YC, Yen CC, Liu CY, Chao TC, Hsiao LT, Liu JH, Chiou TJ, Tzeng CH.

Intern Med. 2014;53(2):95-101. Epub 2012 Mar 1.

5.
6.

The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.

Hong JY, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS.

Ann Oncol. 2014 Jan;25(1):182-8. doi: 10.1093/annonc/mdt530.

PMID:
24356628
7.

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.

J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.

8.

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.

Yhim HY, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY.

BMC Cancer. 2010 Jun 22;10:321. doi: 10.1186/1471-2407-10-321.

9.

Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):671-9. doi: 10.1016/j.clml.2015.07.639. Epub 2015 Aug 5.

PMID:
26361646
10.

A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.

Li X, Xia B, Guo S, Zhan Z, Zhang L, Zhao D, Wu X, Zhang Y.

Ann Hematol. 2013 Jun;92(6):807-15. doi: 10.1007/s00277-013-1701-9. Epub 2013 Feb 17.

PMID:
23417758
11.

Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.

Wolach O, Fraser A, Luchiansky M, Shapiro C, Radnay J, Shpilberg O, Lishner M, Lahav M.

Hematol Oncol. 2015 Mar;33(1):42-7. doi: 10.1002/hon.2127. Epub 2014 Jan 27.

PMID:
24470400
12.

High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.

Song MK, Yang DH, Lee GW, Lim SN, Shin S, Pak KJ, Kwon SY, Shim HK, Choi BH, Kim IS, Shin DH, Kim SG, Oh SY.

Leuk Res. 2016 Mar;42:1-6. doi: 10.1016/j.leukres.2016.01.010. Epub 2016 Jan 24.

PMID:
26851438
13.
14.

Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience.

Wu H, Zhang L, Shao H, Sokol L, Sotomayor E, Letson D, Bui MM.

Br J Haematol. 2014 Jul;166(1):60-8. doi: 10.1111/bjh.12841. Epub 2014 Mar 27.

PMID:
24673481
15.

Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.

J Clin Oncol. 2011 Apr 10;29(11):1452-7. doi: 10.1200/JCO.2010.33.3419. Epub 2011 Mar 7.

PMID:
21383296
16.

[Clinical characteristics and outcomes of 31 patients with primary bone lymphoma].

Zhu Y, Yue C, Wu B, Ping B.

Nan Fang Yi Ke Da Xue Xue Bao. 2013 Mar;33(3):444-7. Chinese.

17.

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.

Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM.

Ann Oncol. 2006 Jan;17(1):123-30. Epub 2005 Oct 19.

PMID:
16236753
18.

Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival.

Bairey O, Shvidel L, Perry C, Dann EJ, Ruchlemer R, Tadmor T, Goldschmidt N.

Cancer. 2015 Sep 1;121(17):2909-16. doi: 10.1002/cncr.29487. Epub 2015 Jun 19.

19.

Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.

Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A.

Ann Oncol. 2014 Jan;25(1):171-6. doi: 10.1093/annonc/mdt481. Epub 2013 Dec 3.

PMID:
24299961
20.

A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.

Mian M, Augustin F, Kocher F, Gunsilius E, Willenbacher W, Zabernigg A, Zangerl G, Oexle H, Schreieck S, Schnallinger M, Fiegl M.

Anticancer Res. 2014 May;34(5):2559-64.

PMID:
24778077

Supplemental Content

Support Center